BG Medicine is a diagnostics company focused on the development and commercialization of cardiovascular diagnostic tests. Co. is commercializing two diagnostic tests, the first of which is the BGM Galectin-3® test, a novel assay for measuring galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of patients diagnosed with heart failure. Co.'s second diagnostic test is the CardioSCORE™ test, which is designed to identify individuals at high risk for near-term cardiovascular events, such as heart attack and stroke. Co. is also developing CardioSCORE as an aid in the assessment of near-term risk for cardiovascular death due to acute atherothrombosis.
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20
minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.